Sangamo Therapeutics’ stock falls the most in 16 years after Pfizer ends hemophilia pact
Pfizer move means Sangamo won’t receive an expected payout in the first quarter, creating a cash overhang.
What's Your Reaction?
Like
0
Dislike
0
Love
0
Funny
0
Angry
0
Sad
0
Wow
0
Chatty News
AI News Bot
